Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
HCM 
HUTCHMED DRC (HCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: HCM (1-star) is a SELL. SELL since 2 days. Profits (-15.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -19.36% | Avg. Invested days 47 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.75B USD | Price to earnings Ratio 76.25 | 1Y Target Price 26.43 |
Price to earnings Ratio 76.25 | 1Y Target Price 26.43 | ||
Volume (30-day avg) 89557 | Beta 0.72 | 52 Weeks Range 12.84 - 21.92 | Updated Date 04/4/2025 |
52 Weeks Range 12.84 - 21.92 | Updated Date 04/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 5.99% | Operating Margin (TTM) -4.99% |
Management Effectiveness
Return on Assets (TTM) -2.14% | Return on Equity (TTM) 5.04% |
Valuation
Trailing PE 76.25 | Forward PE 51.02 | Enterprise Value 1885531462 | Price to Sales(TTM) 4.36 |
Enterprise Value 1885531462 | Price to Sales(TTM) 4.36 | ||
Enterprise Value to Revenue 2.99 | Enterprise Value to EBITDA 133.67 | Shares Outstanding 170976992 | Shares Floating 504595067 |
Shares Outstanding 170976992 | Shares Floating 504595067 | ||
Percent Insiders 0.12 | Percent Institutions 4.04 |
Analyst Ratings
Rating 4.6 | Target Price 46.75 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
HUTCHMED DRC
Company Overview
History and Background
HUTCHMED Limited, formerly Hutchison China MediTech Limited, was founded in 2000. It focuses on discovering, developing, and commercializing innovative therapeutics in oncology and immunology. It has evolved from a traditional Chinese medicine company to a globally-focused biopharmaceutical company.
Core Business Areas
- Oncology: Research, development, and commercialization of targeted therapies and immunotherapies for cancer.
- Immunology: Research, development, and commercialization of therapies for immunological diseases.
Leadership and Structure
The leadership team consists of senior executives with experience in pharmaceutical development and commercialization. The organizational structure is based around research and development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- Elunate (fruquintinib): A highly selective VEGFR inhibitor for metastatic colorectal cancer (mCRC). It holds a significant market share in China for third-line mCRC treatment. Competitors include other chemotherapy regimens and targeted therapies.
- Orpathys (savolitinib): A selective MET inhibitor for non-small cell lung cancer (NSCLC). It is approved in China. Competitors include other targeted therapies for NSCLC.
- Sulanda (surufatinib): An inhibitor of VEGFR, FGFR, and CSF-1R, approved in China for neuroendocrine tumors (NET). Competitors include somatostatin analogs and other targeted therapies.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly oncology and immunology, is characterized by high growth, intense competition, and significant regulatory hurdles.
Positioning
HUTCHMED DRC is positioned as an innovative biopharmaceutical company focused on developing and commercializing novel cancer and immunology therapies, primarily targeting the Chinese market and expanding globally. It is a leader in novel therapies that could not be found in the Chinese market at its conception.
Total Addressable Market (TAM)
The TAM for oncology and immunology therapeutics is substantial and growing. HUTCHMED DRC is positioned to capture a portion of this TAM through its innovative pipeline and commercialization efforts.
Upturn SWOT Analysis
Strengths
- Innovative drug pipeline
- Strong presence in the Chinese market
- Experienced management team
- Proprietary drug discovery platforms
Weaknesses
- Reliance on regulatory approvals
- High R&D expenses
- Competition from larger pharmaceutical companies
- Geographic concentration in China
Opportunities
- Expansion into new markets
- Strategic partnerships and collaborations
- Development of new therapies for unmet medical needs
- Increasing healthcare spending in China
Threats
- Regulatory changes
- Patent expirations
- Competition from biosimilars and generics
- Economic downturns
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- PFE
Competitive Landscape
HUTCHMED DRC competes with larger pharmaceutical companies. Its advantage lies in its focus on innovative therapies and its strong presence in the Chinese market. However, it faces challenges due to its smaller size and limited resources.
Major Acquisitions
No significant acquistions recently
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by product sales in China and pipeline advancement.
Future Projections: Future growth is projected to be driven by expansion into new markets, pipeline advancement, and regulatory approvals.
Recent Initiatives: Recent initiatives include expanding commercial operations, advancing clinical trials, and securing regulatory approvals for new products.
Summary
HUTCHMED DRC is a growing biopharmaceutical company with a strong presence in the Chinese market and an innovative drug pipeline. The company's strength lies in its focus on oncology and immunology and its experienced management team. Challenges include regulatory hurdles, competition from larger pharmaceutical companies, and high R&D expenses. Recent initiatives include expanding commercial operations and advancing clinical trials, which if successful should have it in a better financial position.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
GILD
Gilead Sciences Inc
GILD
Gilead Sciences Inc
MRK
Merck & Company Inc
MRK
Merck & Company Inc
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HUTCHMED DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-03-17 | CEO, Chief Scientific Officer & Executive Director Dr. Wei-Guo Su B.Sc., Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1811 | Website https://www.hutch-med.com |
Full time employees 1811 | Website https://www.hutch-med.com | ||
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.